Abstract. The aim of this study was to compare the effectiveness of transient prehypertensive treatment with losartan compared with amlodipine in spontaneously hypertensive rats (SHRs) on long-term blood pressure (BP), cardiac and renal protection. SHRs were prehypertensively treated with losartan, amlodipine or saline. Rats were followed up until 46 weeks of age. The left ventricular (LV) geometry and function were assessed by echocardiography. Angiotensin II (Ang II) and aldosterone (Aldo) were measured by radioimmunoassay. Ang II type 1 (AT$_1$R) and type 2 (AT$_2$R) receptor protein expression was determined by western blotting. The systolic blood pressure (SBP) in losartan-treated SHRs (SHR-Los) was persistently reduced until 46 weeks of age, but returned to untreated SHR levels in amlodipine-treated SHRs (SHR-Aml) from 30 weeks onwards. Compared to untreated SHRs, the albuminuria excretion in SHR-Los at week 46 was markedly decreased, the plasma, myocardium and renal tissue Ang II and Aldo levels in SHR-Los at week 46 were markedly decreased; AT$_1$R and TGF-$eta_1$ protein expression was downregulated and AT$_2$R protein was upregulated. Compared to untreated SHRs, the left ventricular mass index (LVMI) and collagen volume fraction (CVF) in SHR-Los were markedly decreased until week 46, and the left ventricular ejection fraction (LVEF) and cardiac brain natriuretic peptide mRNA expression were improved, whereas similar LVMi and elevated CVF were observed in SHR-Aml, and the LVEF decreased significantly below that of untreated SHRs at week 46, with cardiac BNP mRNA expression increasing slightly. Prehypertensive treatment with losartan was more effective than amlodipine on delaying long-term BP increase and ameliorating cardiac, renal structure and function, which may be related to the permanent attenuation of the circulating and local renin-angiotensin systems.

Introduction

Evidence has demonstrated that individuals with prehypertension are at an increased risk of developing hypertension and suffering cardiovascular events, poor cognitive performance, type 2 diabetes, as well as kidney damage (1-5). Lifestyle modification is recommended as a basis for all subjects belonging to this blood pressure (BP) category by current guidelines for hypertension, and drug therapy is considered for individuals with hypertension concomitant with diabetes or kidney disease when a trial of lifestyle modification fails to reduce their BP to 130/80 mmHg or less (6). However, poor adherence makes its implementation into clinical settings difficult and relatively ineffective. Recently published TROPHY and PHARAO trials demonstrated that prehypertensive treatment with a renin-angiotensin system (RAS) inhibitor over a relatively short time reduces the risk of incident hypertension and is well tolerated (7,8). In addition, studies using spontaneously hypertensive rats (SHRs) also indicate that early and transient treatment with an angiotensin-converting-enzyme inhibitor (ACEI), angiotensin-receptor blockers (ARB) or aldosterone (Aldo) antagonist attenuates the development of hypertension and exerts cardiovascular protective effects up to an advanced age (9-11).

The aforementioned studies suggest that the renin-angiotensin-Aldo system (RAAS) blockade may be a feasible and beneficial option for individuals with prehypertension, which raises the question whether the effects are restricted only to RAAS antagonists or whether they may also be extended to other forms of therapies, such as calcium channel blockers (CCBs). To our knowledge, this question remains unanswered.

CCBs are a heterogeneous class of drugs used in the treatment of coronary heart disease and hypertension. Amlodipine, a third-generation dihydropyridine CCB, is characterized by high vascular selectivity and relatively low negative inotropic effects. Previous studies involving animal models have proven that amlodipine is effective in preventing hypertension-related left ventricular hypertrophy (LVH) and dysfunction (12,13).
However, research concerned with its use in the prehypertensive stage remains limited.

In the present study, we aimed to compare the effectiveness of prehypertensive treatment with losartan compared with amlodipine in SHRs on long-term BP, renal and cardiac protection, and to investigate the underlying mechanism of their effects.

Materials and methods

Animals and pharmacological treatment. A total of 72 four-week-old male SHRs (purchased from Shanghai Slac Laboratory Animal Co., Ltd.) were randomly divided into 3 groups and were administered losartan [losartan-treated SHRs (SHR-Los), 20 mg/kg/day, n=24], amlodipine [amlodipine-treated SHRs (SHR-Aml), 10 mg/kg/day, n=24] or saline (SHRs, n=24) by gavage for 6 weeks. Age- and gender-matched Wistar-Kyoto rats (WKYs, n=24) served as the normal control. Rats were housed 5/cage under controlled temperature and humidity (60%) conditions, and were exposed to a 12-h dark-light cycle. Standard food and tap water were supplied ad libitum. All experiments were approved by the Animal Ethics Committee of Fujian Medical University and performed in accordance with institutional guidelines.

Experimental protocol. Rats were followed up until week 46. Systolic blood pressure (SBP) was measured at weeks 4 and 10 and monthly after treatment was stopped. Cardiac, renal structure and function, circulating and local RAS components were repeatedly assessed at weeks 14, 30 and 46, with 8 rats sacrificed/group at each time point for analysis. Cardiac, renal and atrophic stage remains limited.

Evaluation of cardiac hypertrophy and fibrosis. Under anesthesia with chloral hydrate (300 mg/100 g, i.p.), the animals were sacrificed and the hearts were removed and blotted dry, the left ventricle (LV) was carefully dissected and weighed, the left ventricle (LV) was dissected and weighed, and the left ventricular mass index (LVMI) (LV weight/100 g body weight) was calculated to indicate cardiac hypertrophy. Then, the hearts were further incubated for 24 h in formalin, embedded in paraffin and cut into 4-µm sections for Sirius Red staining. Sections were carefully scanned with a light microscope (Olympus, Japan) connected to a computer using the Image Pro Plus 6.0 software for histomorphometry at a magnification of x100. The collagen volume fraction (CVF), an index of cardiac fibrosis, was determined as the percentage of the Sirius Red-stained area/total myocardial tissue area.

Echocardiography. Transthoracic echocardiography was performed on the animals in the left lateral decubitus position, after being anesthetized with chloral hydrate (300 mg/100 g, i.p.). A vivid 7 echocardiographic system (GE Healthcare, USA) with a 10-MHz transducer was used to obtain an M-mode echocardiogram from the long axis view of the LV. The left ventricular end-diastolic dimension (LVEDD), end-diastolic interventricular septum thickness (IVSTd) and left ventricular ejection fraction (LVEF) were measured following the guidelines of the American Society of Echocardiography (15).

24-h urinary albumin and creatinine clearance rate. The 24-h urine excretion was collected in metabolic cages. These studies were performed during the same weeks as the echocardiography. Urinary albumin was measured by immunoephelometric analysis (BN-II analyzer; Dade Behring, Eschborn, Germany). Creatine in serum and urine were measured by the sarcosine oxidase enzymic method using an automatic Biochemistry Analyzer (AU2700; Olympus) to calculate the creatinine clearance rate (CCr) with the standard formula: CCr = (urine creatinine x 24-h urine flow)/(serum creatinine x 1440) mg/min.

Renal histology. The kidneys were removed from the animals under pentobarbital sodium anesthesia, fixed in 4% formalin and embedded in paraffin. Central cross-sections of the whole kidney including the cortex and medulla were prepared for examination. The glomerulosclerosis index (GSI) was measured in 4-µm sections, stained with periodic acid-Schiff. GSI was calculated in both superficial and juxtaglomerular glomeruli for the whole interstitial area with a light microscope (Olympus) by a nephropathologist in a blinded manner using a cumulative semi-quantitative scoring as previously described (16).

Plasma, renal cortex tissue and myocardium angiotensin II (Ang II) and Aldo. The heart and renal cortex tissues were weighed (100 mg), boiled and homogenized by Polytron in 1 ml PBS, respectively. The homogenate was centrifuged at 3,500 rpm for 10 min. The tissue supernatant and plasma Ang II and Aldo levels were determined by radioimmunoassay using a commercially available kit (Beijing North Institute of Biological Technology, Beijing, China).

Western blot analysis for AT1R and AT2R proteins. Western blot analysis was performed as described by Xu et al. (17) Briefly, LV tissue (10 mg) and renal cortex tissue (10 mg) were electrophoresed on SDS-polyacrylamide gels under reducing conditions, respectively. Proteins were transferred onto nitrocellulose membranes, blocked with 5% non-fat milk in TBS containing 0.05% Tween-20 (TBST) and then incubated with an anti-AT1R antibody (1:500, ab9391; Abcam), anti-AT2R antibody (1:800, ab19134; Abcam) or anti-actin antibody (1:1000, sc-1616; Santa Cruz Biotechnology, Inc.) overnight at 4°C. After 5 washes with TBST and 2 washes with TBS, the membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody. Following another 2 washes with TBST, labeled proteins were visualized using ECL (sc-2048; Santa Cruz Biotechnology, Inc.) on high-performance chemiluminescence film. The intensity of the bands was quantified by densitometry with image analysis software. Results for AT1R and AT2R were expressed as a ratio of AT1R or AT2R over β-actin.
Quantification of cardiac BNP mRNA. Total RNA from ventricular tissue was isolated with TRIzol reagent (Invitrogen), and the concentration was determined by measuring the absorbance at 260 nm. The RNA was transcribed into cDNA using M-MLV reverse transcriptase (Promega) and amplified (Takara PCR Amplification kit) using primers (Table I) specific to each gene of interest. The cycle profiles were programed as follows: initial 5-min denaturation at 95˚C followed by 35 cycles of denaturation at 95˚C for 30 sec, annealing at 59 or 55˚C (for BNP and GAPDH, respectively) for 30 sec and extension at 72˚C for 30 sec, with a final extension at 72˚C for 5 min. PCR products were analyzed by 1.5% agarose gel electrophoresis. The photodensity of amplified cDNA product bands was quantified by densitometry. The BNP mRNA abundance was defined as a ratio to GAPDH mRNA.

Statistical analysis. All analyses were performed with SPSS software version 13.0 (Chicago, IL, USA). Continuous data are presented as the means ± standard deviation (SD). Differences between groups were compared by one-way analysis of variance, followed by LSD t-test for multiple comparisons. P<0.05 values were considered to indicate a statistically significant difference. For all tests, a two-tailed P-value <0.05 was considered to indicate a significant result.

Results

Systolic blood pressure. At week 10, the SBP in the untreated SHRs was significantly higher compared to that in the WKYs (SHRs vs. WKYs: 170±5 vs. 116±8 mmHg, P<0.05). Prehypertensive treatment with losaratan and amloidipine equally reduced BP to a midway level between untreated SHRs and WKYs (SHR-Los vs. SHR-Aml: 126±6 vs. 124±7 mmHg; P>0.05). After drug withdrawal, the SBP in SHR-Los remained significantly lower compared to that in untreated SHRs until week 46 (P<0.05), whereas SBP gradually increased to untreated SHR levels in SHR-Aml from 30 weeks onwards (P>0.05) (Fig. 1).

Evaluation of cardiac hypertrophy and fibrosis. Cardiac hypertrophy and fibrosis, expressed by the left ventricular hypertrophy index and myocardial CVF, respectively, were both significantly elevated in untreated SHRs compared with WKYs throughout the study (P<0.05). The LVMI and CVF in SHR-Los displayed similar values compared to those in WKYs at week 14 (LVMI, 2.29±0.34 vs. 2.33±0.21 mg/g; CVF, 2.6±0.7 vs. 2.6±0.4%, both P>0.05) and remained midway between untreated SHRs and WKYs at weeks 30 and 46 (P<0.05). Unlike losaratan treatment, the LVMI in SHR-Aml was not different from that in untreated SHRs at weeks 14 and 46 (P>0.05), but was slightly reduced at week 30 (2.61±0.18 vs. 3.11±0.09 mg/g, P<0.05) (Fig. 2A); the CVF in SHR-Aml demonstrated comparable values to untreated SHRs at weeks 14 and 30 (P>0.05), but was significantly higher compared to that in untreated SHRs at week 46 (12.1±1.3 vs. 7.8±1.5%, P<0.05) (Fig. 2B).

Echocardiography. As shown in Table II, the IVSTd in untreated SHRs was significantly higher compared to that in WKYs throughout the experiment (P<0.05), and the IVSTd in SHR-Los revealed similar values as in WKYs (P>0.05), whereas an insignificant reduction of IVSTd was observed in SHR-Aml compared with untreated SHRs (P>0.05). The LVEDDs in the WKY and SHR-Los groups remained stable over the follow-up period, but increased progressively in untreated SHRs and SHR-Aml at week 46 as compared to previous values. The LVEF deteriorated significantly in untreated SHRs and even more sharply in SHR-Aml as compared with WKYs at week 46 (SHR, 79.5±1.9%; SHR-Aml, 74.4±4.3%; WKY, 84.2±2.3%; both P<0.05), but values remained similar for the WKY and SHR-Los groups (83.1±2.3%).

Renal state until advanced age. Compared with WKYs, 24-h albuminuria was increased in untreated SHRs and prehypertensively treated SHRs throughout the study.

Table I. Primer sequences.

| Primer | Sequence 5’ to 3’ Annealing temperature (˚C) Amplification product (bp) |
|--------|--------------------------------------------------|------------------|
| BNP    | Up GCTGCTTTGGCCAGAAAGATAGA  59 169 Down ACAACCTCAGCCCAGTCACA | |
| GAPDH  | Up CAACGGCACAGTCAGAGG 55 468 Down CCAGTGGATGCAGGGAT | |

BNP, brain natriuretic peptide; GAPDH, glyceraldehyde phosphate dehydrogenase.
Figure 2. (A) Comparison of the long-term effects on LVMI with prehypertensive losartan and amlodipine treatment. (B) Comparison of the long-term effects on CVF with prehypertensive losartan and amlodipine treatment. Myocardial interstitial collagen appears in red and cardiac myocytes in yellow after picrosirius red staining. Original magnification, x10. *P<0.05 vs. SHRs at the same age; #P<0.05 vs. WKYs at the same age; &P<0.05 vs. SHR-Los at the same age. LVMI, left ventricular mass index; CVF, collagen volume fraction.

Table II. Longitudinal echocardiographic evaluation of WKYs, untreated and prehypertensively treated SHRs.

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (Weeks)</th>
<th>IVSTd (mm)</th>
<th>LVEDD (mm)</th>
<th>EF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td>14</td>
<td>2.52±0.23</td>
<td>6.9±0.6</td>
<td>83.2±2.9</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>2.64±0.17</td>
<td>6.9±0.6</td>
<td>83.5±2.7</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>2.60±0.25</td>
<td>7.6±0.7(^d)</td>
<td>79.5±1.9</td>
</tr>
<tr>
<td>WKY</td>
<td>14</td>
<td>1.72±0.07(^a)</td>
<td>7.2±0.6</td>
<td>85.1±2.2</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>1.96±0.11(^a)</td>
<td>7.3±0.4</td>
<td>85.1±1.8</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>1.92±0.22(^a)</td>
<td>7.3±0.5</td>
<td>84.2±2.3(^a)</td>
</tr>
<tr>
<td>SHR-Los</td>
<td>14</td>
<td>1.78±0.12(^a)</td>
<td>7.2±0.9</td>
<td>83.2±3.2</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>1.85±0.13(^a)</td>
<td>7.2±0.5</td>
<td>82.8±2.5</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>1.88±0.16(^a)</td>
<td>7.3±0.4</td>
<td>83.1±2.3(^a)</td>
</tr>
<tr>
<td>SHR-Aml</td>
<td>14</td>
<td>2.62±0.15(^b,c)</td>
<td>6.8±0.7</td>
<td>82.7±3.1</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>2.54±0.21(^b,c)</td>
<td>7.0±0.3</td>
<td>80.5±4.6</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>2.52±0.22(^b,c)</td>
<td>7.8±0.7(^d)</td>
<td>74.4±4.3(^c)</td>
</tr>
</tbody>
</table>

IVSTd, end-diastolic interventricular septum thickness; LVEDD, left ventricular end-diastolic dimension; EF, ejection fraction. *P<0.05 vs. SHRs at the same age; \(^a\)P<0.05 vs. WKYs at the same age; \(^b\)P<0.05 vs. SHR-Los at the same age; \(^c\)P<0.05 vs. previous follow-up time.
The plasma Ang II in untreated SHRs was comparable to WKYs at weeks 14 and 30, but was significantly higher compared to that in WKYs at week 46 (P<0.05). At weeks 30 and 46, the plasma Ang II in SHR-Los was significantly reduced compared with the untreated SHR and WKY groups (P<0.05), whereas the plasma Ang II in SHR-Aml exhibited similar values to untreated SHRs (P>0.05). The difference in plasma Aldo between untreated SHR and WKY groups was consistent with that in plasma Ang II throughout the study period. The plasma Aldo in SHR-Los was permanently attenuated compared with untreated SHRs (P<0.05), however, no significant difference of plasma Aldo was observed between the SHR-Aml and untreated SHR groups (P>0.05) (Fig. 4A and B). The Ang II and Aldo of renal cortex tissue and myocardium in untreated SHRs were markedly higher compared to those in WKYs throughout the follow-up period. The myocardium Ang II and Aldo in SHR-Los were significantly decreased compared with untreated SHRs (P<0.05), whereas no significant difference of myocardium Ang II and Aldo was observed between the SHR-Aml and untreated SHR groups (P>0.05) (Fig. 4C and D). The renal cortex tissue Ang II and Aldo in SHR-Los were significantly decreased compared with untreated SHRs (P<0.05), whereas no significant difference of renal cortex tissue Ang II and Aldo was observed between the SHR-Aml and untreated SHR groups (P>0.05) (Fig. 4E and F and Table IV).

**Western blot analysis for AT, R and AT, R proteins.** At weeks 14 and 46, the cardiac AT, R protein expression in untreated SHRs was significantly higher compared to that in WKYs (P<0.05), and the reverse occurred for the AT, R protein (P<0.05) (Fig. 5). The AT, R protein expression was downregulated while the AT, R protein was upregulated in the SHR-Los group as compared with untreated SHRs; no significant difference of the two protein levels was observed between the SHR-Aml and untreated SHR groups (P>0.05). The renal AT, R and AT, R protein expression levels were...
similar to the results of the cardiac levels at weeks 14 and 46, and TGF-β₁ protein expression in untreated SHRs was significantly higher compared to that in WKYs (P<0.05). The renal TGF-β₁ protein expression was lower in SHR-Los as compared with untreated SHRs, and no significant difference of the two protein levels was observed between the SHR-Aml and untreated SHR group (Fig 6).

Quantification of cardiac BNP mRNA. At week 46, the cardiac BNP mRNA expression in untreated SHRs was notably
higher compared to that in WKYs (P<0.05), the cardiac BNP mRNA in SHR-Los was observably decreased as compared with untreated SHRs, but was still higher compared to that in WKYs (P<0.05) (Fig. 7). In contrast, the cardiac BNP mRNA expression in SHR-Aml was slightly and significantly increased compared with untreated SHRs (P<0.05).

Table IV. Evaluation of longitudinal plasma and renal cortex tissue Ang II and Aldo levels of WKYs, untreated and prehypertensively treated SHRs (n=8).

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (Weeks)</th>
<th>Plasma Ang II (pg/ml)</th>
<th>Plasma Aldo (ng/ml)</th>
<th>Renal cortex tissue Ang II (pg/100 mg)</th>
<th>Renal cortex tissue Ang II (ng/100 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td>14</td>
<td>385.02±45.24</td>
<td>0.21±0.033</td>
<td>85.15±5.53</td>
<td>0.79±0.076</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>403.23±36.86</td>
<td>0.23±0.031</td>
<td>80.66±6.54</td>
<td>0.88±0.035</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>458.88±32.48</td>
<td>0.25±0.041</td>
<td>81.34±7.03</td>
<td>0.86±0.041</td>
</tr>
<tr>
<td>WKY</td>
<td>14</td>
<td>358.18±78.02</td>
<td>0.20±0.026</td>
<td>48.24±5.71</td>
<td>0.41±0.055</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>385.23±41.43</td>
<td>0.20±0.029</td>
<td>41.64±5.79</td>
<td>0.45±0.041</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>367.71±43.69</td>
<td>0.21±0.019</td>
<td>41.70±5.02</td>
<td>0.42±0.071</td>
</tr>
<tr>
<td>SHR-Los</td>
<td>14</td>
<td>485.18±94.25</td>
<td>0.13±0.021</td>
<td>50.90±6.61</td>
<td>0.57±0.035</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>319.92±53.78</td>
<td>0.15±0.020</td>
<td>57.21±4.17</td>
<td>0.62±0.042</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>302.11±32.36</td>
<td>0.17±0.020</td>
<td>57.70±6.31</td>
<td>0.57±0.056</td>
</tr>
<tr>
<td>SHR-Aml</td>
<td>14</td>
<td>478.92±73.99</td>
<td>0.19±0.019</td>
<td>84.75±4.96</td>
<td>0.76±0.071</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>391.39±40.56</td>
<td>0.22±0.036</td>
<td>76.89±3.31</td>
<td>0.82±0.022</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>458.91±46.26</td>
<td>0.25±0.036</td>
<td>80.51±4.07</td>
<td>0.81±0.052</td>
</tr>
</tbody>
</table>

*P<0.05 vs. SHRs at the same age;  †P<0.05 vs. SHR-Los at the same age. The data are represented as the means ± SD.
Discussion

In the present study, we demonstrated that transient prehypertensive treatment with losartan was more effective than amlodipine in delaying a long-term blood pressure (BP) increase and ameliorating renal, cardiac structure and function, and that the mechanism responsible for losartan’s superiority may be due to its permanent attenuation of both circulating and local renin-angiotensin systems (RAS).

Our results demonstrated that although the antihypertensive effects were similar between the two therapeutic regimens during treatment, BP development differed significantly after drug withdrawal. BP in losartan-treated SHRs (SHR-Los) remained significantly lower compared to that in untreated SHRs until week 46, whereas BP in amlodipine-treated SHRs (SHR-Aml) returned to untreated SHR levels from 30 weeks onwards. This finding notably coincides with a previous study by Christensen et al. (18) that SHR treatment with angiotensin-converting-enzyme inhibitor (ACEI) rather than β-blocker, vasodilator or calcium antagonist prevented BP increase after withdrawal of long-term treatment. Whether or not the ACEI or angiotensin-receptor blockers (ARB) had longer effects on BP reduction compared to other forms of therapies remains unclear. One possibility is related to the ‘RAS block memory’ via suppression of a ‘reno-vascular amplifier’ mechanism (19-21). According to this hypothesis, during the critical period of hypertension development in juveniles, increased BP leads to vascular hypertrophy in the resistance vessels, which decreases glomerular perfusion and results in increased synthesis of renin and activation of RAS. These changes cause a further BP increase and initiate a positive feedback loop. RAS inhibitors may block this vicious cycle by attenuating the rise in BP and importantly, by decreasing the vascular hypertrophy. Other possibilities are that alterations in the central RAS, decreases in plasma AVP levels and alterations in endothelial function may be involved in the prolonged hypotensive effect (22-24). Recently Baumann et al. (25) demonstrated that a BP decrease after transient ARB is associated with an increased medullary blood flow and a reduced medullary pericyte number. These possibilities are not mutually exclusive, and it is possible that multiple mechanisms may be involved in the sustained suppression of BP. As to the prolonged pressure-lowering effects of amlodipine, BP development after drug withdrawal in our study was different from the result reported by Sevilla et al. (26). They indicated that treatments of adult SHRs with 8 and 20 mg/kg/day of amlodipine for six months yielded...
persistent hypotensive effects even at three months after drug withdrawal. A potential reason for this difference was that amlodipine treatment was administered too early and for a limited time period to reverse vascular hypertrophy and break the vicious cycle.

With respect to the effects on cardiac protection, our results demonstrated that prehypertensive treatment with losartan permanently reduced cardiac hypertrophy and fibrosis until week 46. Longitudinal echocardiographic evaluation revealed identical values of interventricular septum thickness (IVSTd) between SHR-Los and WKYs, and the left ventricular end-diastolic dimension (LVEDD) remained stable over the follow-up period. Besides these, the left ventricular ejection fraction (LVEF) and cardiac BNP mRNA expression were improved in SHR-Los compared with untreated SHRs at week 46. All the above changes suggest prolonged cardioprotective effects by losartan treatment. The mechanism to determine how transient prehypertensive treatment with losartan exerts sustained cardiac protection is required. Previous studies have mainly explained the mechanism through the reduction of gene expression of cardiac Ang II type 1 receptor (AT\_1R) (10) or plasma Ang II concentration (27) and not by a BP decrease alone. In our study, we measured the circulating and local angiotensin II and Aldo levels by radioimmunoassay and discovered that, besides the suppressant effects on circulating RAS (at week 14, the plasma Ang II was elevated via negative feedback regulation), the cardiac RAS was also significantly inhibited, which has been proven to be involved in the pathogenesis of cardiac hypertrophy and fibrosis (28,29). Furthermore, western blot analysis detected a favorably altered AT\_1R/AT\_2R balance with losartan treatment, which consisted of downregulated cardiac AT\_1R protein but upregulated AT\_2R protein. Although how low levels of local Ang II act on high levels of AT\_1R to...
ameliorate cardiac damage remains unknown, our results revealed that transient prehypertensive treatment with losartan may maintain the circulating and local RAS in an initial low-activity or physiologic state. Unlike the results reported by Baumann et al (10) the SBP in our study remained lower compared to the untreated SHRs during the experimental period; thus, it cannot be precluded that the beneficial effects of losartan treatment is related to a BP decrease alone.

Noteworthy, the LVMi in amlodipine-treated SHR was similar to that in untreated SHRs at weeks 14 and 46, but was significantly decreased at week 30. The possible reason for this phenomenon is that the cardiac hypertrophy of SHRs is fully established between week 14 and 30 (30), and amlo-
dipine treatment causes hypertrophy regression via its residual pressure reduction during this period and the antihypertrophy action tapers with the disappearance of antihypertensive effects from 30 weeks onwards. Unexpectedly, the SHR-Aml exhibited no difference in CVF from untreated SHRs at weeks 14 and 30, but an observably higher value compared to the untreated SHRs at week 46. Moreover, the echocardiography displayed enlarged LVEDD and declined EF at the end of follow-up, and RT-PCR assay detected a slightly and significantly increased expression of BNP mRNA. These results implied a detrimental effect of amlodipine treatment, which we speculated may be related to the negative inotropic effects of amlodipine since the plasma and myocardium Ang II and Aldo levels were comparable between SHR-Aml and untreated SHRs at week 46. Our speculation contradicted the commonly accepted properties of amlodipine of insignifi-
cant negative inotropic effects (31). The specific intervention period or inappropriate dose of amlodipine in our study may be responsible for this discrepancy, yet a detailed mechanism needs to be further investigated.

Circulating RAS regulates physiological responses, whereas the local RAS is activated during tissue injury and contributes to pathological processes, including cell prolifera-
tion/apoptosis, fibrosis and inflammation. Ang II is one key factor in the development of renal fibrosis. In this study, our data demonstrated that transient prehypertensive treatment with losartan reduces Ang II and Aldo concentrations both in plasma and myocardium, whereas the local RAS is activated during tissue injury and regulating AT1R protein expression. It revealed that transient prehypertensive treatment with losartan may maintain the circulating and local RAS in a low-activity state. Furthermore, AT1R upregulation in SHR-Los inhibits progress of glomerulosclerosis, supporting key effects of AT1R/AT1R balance in fibrotic states. Although regulation of the expression of the AT1R is poorly understood, previous studies have proven the AT1R actions contribute to ARB effects in the kidney (32).

In summary, our results suggest that transient AT1R blockade in young SHRs is superior to the calcium antagonist on delaying long-term BP rise and ameliorating cardiac, renal structure and function, which corroborated the effectiveness and feasibility of an RAS inhibitor for prehypertensive treatment demonstrated by TROPHY and PHARAO trials. However, the superiority of ARB over a calcium channel blocker (CCB) observed in animal experiments should be cautiously interpreted when translated into clinical settings, since the prehypertensive condition of human beings is far more complicated (e.g., strain difference, attendant obesity, dyslipidemia or impaired glucose tolerance) as compared with SHRs. Moreover, since the recently published trial of DHYPP demonstrated that one year of candesartan treatment in subjects with high familial risk of future hypertension had no persistent effect on BP when treatment was discontinued (33), further studies to explore how to ‘apply’ the prolonged cardioprotective effects observed in animals to human beings is required. Nevertheless, our data have important clinical implications that ARB may be a better choice compared with CCB for hypertension prevention and cardiac protection.

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (81070207). Amlodipine was generously supplied by Pfizer Pharmaceutical, Inc. The authors would like to thank Meiyan Lin and Shusheng Liao for their technical support.

References


12. Tomassoni D, Sabbatini M and Amenta F: Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hyper-

13. Watanabe M, Kawaguchi H, Onozuka H, et al: Chronic effects of enalapril and amlodipine on cardiac remodeling in cardio-

15. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: a report from the American Society of Echo cardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005.


